Making a difference to the people we help treat by creating value and improving healthcare outcomes through connecting innovative manufacturers with Australasian customers.

The 2025-26 Merck Analyte Quarterly Update is Here!

Beyond Biomarkers! 

Expect reliable measurements, a simplified user experience, and knowledgeable scientific partners to help drive your biomarker projects. Abacus dx is committed to delivering the best possible immunoassays from Merck for your research needs.

Whether you are using Merck’s industry-leading MILLIPLEX® multiplex panels to broadly survey multiple analytes, performing femtogram/mL biomarker analysis using the FemtoQuest™ ultrasensitive immunoassay platform, or examining single proteins with our tried-and-true ELISAs and RIAs, you can confidently expect reliable measurements, a simplified user experience, and knowledgeable scientific partners to help drive your biomarker project from hypothesis to publication.

2025-26 Merck Analyte Quarterly Update

Download Here >


2025-26 Merck Analyte Quarterly Update

Download Here >

Request a Quote

Request Quote

Recent Posts

2027 Abacus dx Emerging Investigators Grant

COMING SOON Grant in Research Funding Empowering the Next Generation of Scientific Leaders Stay tuned for the 2027 Abacus dx Emerging Investigators Grant. More information…

Read full article

Developing Diagnostic Kits for Ovarian Cancer

In Australia, ovarian cancer is the deadliest reproductive cancer. The average five‑year survival rate sits at around 49%, compared with about 92% for breast cancer,…

Read full article

Merck FemtoQuest™

Gain your desired immunoassay sensitivity with the ultrasensitive FemtoQuest™ system Measure down to femtogram/mL levels Improved precision and robust data Perform dual-plex and single analyte…

Read full article